Innate Pharma S.A. (IPH.PA)
EUR 1.98
(-3.37%)
EUR 1.98
(-3.37%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 39.89 Million EUR | -5.58% |
| 2022 | 42.25 Million EUR | -4.52% |
| 2021 | 44.25 Million EUR | 131.84% |
| 2020 | 19.08 Million EUR | 1.94% |
| 2019 | 18.72 Million EUR | 314.04% |
| 2018 | 4.52 Million EUR | -22.89% |
| 2017 | 5.86 Million EUR | 10.08% |
| 2016 | 5.32 Million EUR | 41.9% |
| 2015 | 3.75 Million EUR | -10.75% |
| 2014 | 4.2 Million EUR | -12.72% |
| 2013 | 4.81 Million EUR | 6.97% |
| 2012 | 4.5 Million EUR | -65.93% |
| 2011 | 13.22 Million EUR | 94.83% |
| 2010 | 6.78 Million EUR | -10.17% |
| 2009 | 7.55 Million EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | -100.0% |
| 2006 | 3.3 Million EUR | 470.34% |
| 2005 | 580 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 34.91 Million EUR | -12.48% |
| 2024 Q2 | 34.91 Million EUR | 1.68% |
| 2023 Q3 | 39.4 Million EUR | -3.07% |
| 2023 Q4 | 39.89 Million EUR | 1.23% |
| 2023 FY | 39.89 Million EUR | -5.58% |
| 2023 Q1 | 40.1 Million EUR | -5.09% |
| 2023 Q2 | 40.65 Million EUR | 1.39% |
| 2022 Q2 | 43.37 Million EUR | 1.96% |
| 2022 Q1 | 42.54 Million EUR | -3.87% |
| 2022 FY | 42.25 Million EUR | -4.52% |
| 2022 Q4 | 42.25 Million EUR | 1.99% |
| 2022 Q3 | 41.42 Million EUR | -4.49% |
| 2021 Q4 | 44.25 Million EUR | 1.85% |
| 2021 Q2 | 16.5 Million EUR | 5.36% |
| 2021 Q1 | 15.66 Million EUR | -17.94% |
| 2021 FY | 44.25 Million EUR | 131.84% |
| 2021 Q3 | 43.44 Million EUR | 163.28% |
| 2020 Q1 | 18.07 Million EUR | -3.49% |
| 2020 FY | 19.08 Million EUR | 1.94% |
| 2020 Q4 | 19.08 Million EUR | 4.24% |
| 2020 Q3 | 18.31 Million EUR | -2.69% |
| 2020 Q2 | 18.81 Million EUR | 4.13% |
| 2019 Q2 | 4.95 Million EUR | 32.42% |
| 2019 Q3 | 18.08 Million EUR | 264.71% |
| 2019 Q4 | 18.72 Million EUR | 3.52% |
| 2019 Q1 | 3.74 Million EUR | -17.18% |
| 2019 FY | 18.72 Million EUR | 314.04% |
| 2018 FY | 4.52 Million EUR | -22.89% |
| 2018 Q4 | 4.52 Million EUR | 26.7% |
| 2018 Q3 | 3.56 Million EUR | -31.81% |
| 2018 Q2 | 5.23 Million EUR | 23.04% |
| 2018 Q1 | 4.25 Million EUR | -27.46% |
| 2017 FY | 5.86 Million EUR | 10.08% |
| 2017 Q1 | 3.75 Million EUR | -29.43% |
| 2017 Q2 | 4.66 Million EUR | 24.0% |
| 2017 Q4 | 5.86 Million EUR | 18.46% |
| 2017 Q3 | 4.95 Million EUR | 6.2% |
| 2016 Q3 | 4.43 Million EUR | 8.67% |
| 2016 FY | 5.32 Million EUR | 41.9% |
| 2016 Q4 | 5.32 Million EUR | 20.03% |
| 2016 Q2 | 4.08 Million EUR | 15.63% |
| 2016 Q1 | 3.53 Million EUR | -5.91% |
| 2015 FY | 3.75 Million EUR | -10.75% |
| 2015 Q2 | 3.98 Million EUR | 13.12% |
| 2015 Q3 | 3.28 Million EUR | -17.6% |
| 2015 Q4 | 3.75 Million EUR | 14.38% |
| 2015 Q1 | 3.52 Million EUR | -16.29% |
| 2014 Q3 | 3.75 Million EUR | -15.19% |
| 2014 FY | 4.2 Million EUR | -12.72% |
| 2014 Q4 | 4.2 Million EUR | 12.07% |
| 2014 Q1 | 3.98 Million EUR | -17.39% |
| 2014 Q2 | 4.42 Million EUR | 11.15% |
| 2013 Q3 | 4.33 Million EUR | 6.09% |
| 2013 FY | 4.81 Million EUR | 6.97% |
| 2013 Q1 | 3.53 Million EUR | -21.44% |
| 2013 Q2 | 4.08 Million EUR | 15.51% |
| 2013 Q4 | 4.81 Million EUR | 11.11% |
| 2012 Q3 | - EUR | 0.0% |
| 2012 FY | 4.5 Million EUR | -65.93% |
| 2012 Q4 | 4.5 Million EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2011 Q4 | 13.22 Million EUR | 0.0% |
| 2011 FY | 13.22 Million EUR | 94.83% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 FY | 6.78 Million EUR | -10.17% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 Q4 | 6.78 Million EUR | 0.0% |
| 2009 Q4 | 7.55 Million EUR | 0.0% |
| 2009 FY | 7.55 Million EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | -100.0% |
| 2006 FY | 3.3 Million EUR | 470.34% |
| 2005 FY | 580 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -1076.785% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 28.074% |
| Adocia SA | 13.08 Million EUR | -204.806% |
| Aelis Farma SA | 4.03 Million EUR | -887.94% |
| Biophytis S.A. | 8.27 Million EUR | -382.382% |
| Advicenne S.A. | 17.42 Million EUR | -128.941% |
| genOway Société anonyme | 7.23 Million EUR | -451.511% |
| IntegraGen SA | 1.12 Million EUR | -3446.88% |
| Medesis Pharma S.A. | 1.2 Million EUR | -3224.417% |
| Neovacs S.A. | 650 Thousand EUR | -6037.385% |
| NFL Biosciences SA | 62.17 Thousand EUR | -64063.477% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -815.71% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -1368.361% |
| Sensorion SA | 2.86 Million EUR | -1290.588% |
| Theranexus Société Anonyme | 3.64 Million EUR | -995.053% |
| TME Pharma N.V. | 1.16 Million EUR | -3321.355% |
| Valbiotis SA | 6.87 Million EUR | -480.009% |
| TheraVet SA | 1.15 Million EUR | -3339.446% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -343.354% |
| argenx SE | 18.1 Million EUR | -120.339% |
| BioSenic S.A. | 28.16 Million EUR | -41.66% |
| Celyad Oncology SA | 902 Thousand EUR | -4322.727% |
| DBV Technologies S.A. | 13.01 Million USD | -206.431% |
| Galapagos NV | 9.59 Million EUR | -315.725% |
| Genfit S.A. | 70.17 Million EUR | 43.155% |
| GeNeuro SA | 7.73 Million EUR | -415.56% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -653.551% |
| Inventiva S.A. | 37.4 Million EUR | -6.646% |
| MaaT Pharma SA | 14.07 Million EUR | -183.432% |
| MedinCell S.A. | 58.96 Million EUR | 32.34% |
| Nanobiotix S.A. | 50.56 Million EUR | 21.106% |
| Onward Medical N.V. | 16.87 Million EUR | -136.417% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -191.461% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 12.899% |
| Oxurion NV | 12.33 Million EUR | -223.439% |
| Pharming Group N.V. | 155.29 Million EUR | 74.311% |
| Poxel S.A. | 46.9 Million EUR | 14.94% |
| GenSight Biologics S.A. | 18.42 Million EUR | -116.48% |
| Transgene SA | 1.25 Million EUR | -3073.667% |
| Financière de Tubize SA | 79.2 Million EUR | 49.63% |
| UCB SA | 3.03 Billion EUR | 98.687% |
| Valneva SE | 208.81 Million EUR | 80.896% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -104881.579% |